A mid-stage clinical study of RAP-219 is delivering striking results for adults with drug-resistant focal epilepsy, a group that often cycles through multiple medicines with limited relief. As first reported by New Atlas, investigators observed large drops in seizure activity, including a median 77.8% reduction in clinical seizures over eight weeks and seizure-freedom for nearly a quarter of participants—rare outcomes in such a hard-to-treat population.
Who’s behind the progress
The program is led by Boston-based Rapport Therapeutics, a neuroscience biotech developing precision small-molecule medicines. In its official announcement, the company reported that RAP-219 met its primary endpoint—reducing objective “long episodes” captured by implanted neurostimulator devices—and was generally well tolerated. Rapport says it plans two Phase 3 trials following regulatory consultation. You can read the sponsor’s details in the Rapport Therapeutics press release.
Academic leadership matters here, too. The multicenter study includes investigators from NYU Langone Health, where epilepsy specialist Jacqueline French, MD has emphasized the trial’s novel use of continuous electrophysiology from responsive neurostimulation (RNS) systems to anchor endpoints. Coverage in NeurologyLive highlights both the magnitude of the seizure reductions and the objective biomarker approach—an advance that helps translate lab insights into clinical decisions.
Finally, transparency on the protocol and sites comes via public trial registries. The study—NCT06377930—is listed on CenterWatch as an open-label, proof-of-concept trial in 30 adult participants with refractory focal epilepsy, all implanted with RNS for continuous recording. Basic design elements and eligibility criteria are summarized on CenterWatch.
What makes RAP-219 different—and why that’s good news
Most anti-seizure medications act broadly on neuronal excitability, which can curb seizures but also bring sedation, cognitive fog, or motor side effects. RAP-219 was built with a more anatomically selective idea in mind: it modulates AMPA receptors through TARPγ8, a regulatory subunit that is enriched in brain regions—like the neocortex and hippocampus—where focal seizures commonly arise. That targeting is the rationale for achieving strong seizure control while potentially avoiding the “whole-brain” downsides that limit many therapies. Early signals in the trial support this: the drug reduced the study’s objective biomarker of pathologic activity (long episodes) and achieved sizable clinical seizure reductions, with mostly mild to moderate adverse events reported by the sponsor.
Beyond one drug, the study’s method is a win for patients. Using implanted RNS devices to quantify abnormal electrical bursts gives researchers real-time, objective measures that correlate with clinical seizures. That helps de-risk development and makes success (or failure) clearer earlier—potentially speeding useful medicines to people who need them.
Where this could lead next
For people living with uncontrolled focal seizures, any sustained drop in frequency can be life-changing—protecting employment, independence, safety, and mental health. The RAP-219 data point to a credible new option if larger, controlled studies confirm both efficacy and tolerability. According to NeurologyLive, Rapport plans a formal meeting with regulators and expects to start two pivotal studies, a standard path toward potential approval if outcomes hold.
Overall, this moment is encouraging without hype: a purpose-built medicine, a thoughtful clinical design, and collaboration between a biotech sponsor and academic leaders are combining to push the frontier of epilepsy care. If the Phase 3 results echo what’s been seen so far, people with drug-resistant focal epilepsy could soon have a treatment that is both effective and precise—and that’s good news.
More Good News
-
Alzheimer’s risk cut in half by drug in landmark prevention trial
A clinical trial from Washington University in St. Louis and published in The Lancet Neurology found that long-term high-dose treatment with the antibody drug gantenerumab reduced Alzheimer’s risk by roughly 50% in people with dominantly inherited Alzheimer’s disease — a rare genetic form caused by mutations that make the disease near-certain. The results are statistically uncertain and apply to less than 1% of all Alzheimer’s cases, but they provide the first evidence that removing amyloid plaques before symptoms appear can meaningfully change the course of the disease.
-
Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
Marie-Louise Eta, 34, was appointed head coach of Bundesliga side Union Berlin on April 12, 2026, becoming the first woman to hold the top coaching position at a men’s club in any of Europe’s Big Five leagues — the Premier League, La Liga, Serie A, Ligue 1, and Bundesliga. A Champions League winner as a player with Turbine Potsdam in 2010, Eta had already broken barriers as the first female assistant coach in the Bundesliga in 2023. She takes charge for the final five matches of the season as Union Berlin fights to secure top-flight survival, after which she was…
-
Renewables now make up at least 49% of global power capacity
Renewable energy reached 49.4% of total global installed power capacity by end of 2025, up from 46.3% in 2024, according to the International Renewable Energy Agency’s Renewable Capacity Statistics 2026. The world added 692 gigawatts of new renewable capacity last year — the largest annual addition ever recorded — with solar alone contributing 511 gigawatts. Africa recorded its highest renewable expansion on record, and the Middle East its fastest-ever growth. IRENA Director-General Francesco La Camera noted that countries investing in renewables are absorbing the current Middle East energy crisis with measurably less economic damage than fossil-fuel-dependent economies.
-
Global suicide rate has fallen by 40% since 1995
A landmark study published in The Lancet Public Health by researchers at the Institute for Health Metrics and Evaluation at the University of Washington found that the global age-standardized suicide mortality rate fell nearly 40% between 1990 and 2021 — from 15 deaths per 100,000 people to nine. The decline was driven by measurable interventions including restrictions on toxic pesticides, expanded mental health services, and national prevention strategies. Female suicide rates fell more than 50% globally over the period. Roughly 740,000 people still die by suicide each year, and rates have risen in parts of Latin America and North America,…
-
Rhinos are reintroduced back into Uganda’s wild after 43 years
The Uganda Wildlife Authority havetranslocated the first southern white rhinos to Kidepo Valley National Park — 43 years after the last rhino in the park was killed by poachers in 1983. The animals came from Ziwa Rhino Sanctuary, a breeding program established in 2005 with just six individuals that has grown Uganda’s total rhino population to 61. Four more rhinos will follow by May, with a separate group already relocated to Ajai Wildlife Reserve in January 2026. The reintroduction restores a key grazing species to one of Africa’s most remote savannah ecosystems and makes Kidepo the only national park in…
